Sumoylation of the forkhead transcription factor FOXL2 promotes its stabilization/activation through transient recruitment to PML bodies

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Georges, Adrien ^a,b,c   Benayoun, Bérénice A ^a,b   Marongiu, Mara ^d   Dipietromaria, Aurélie ^a,b,e   L'Hôte, David ^a,b   Todeschini, Anne Laure ^a,b   Auer, Jana ^b   Crisponi, Laura ^d   Veitia, Reiner A ^a,b  

^a INSTITUT JACQUES MONOD   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c ECOLE NORMALE SUPÉRIEURE   (France)

^d CNR   (Italy)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; NUCLEAR FACTOR; PROTEIN FOXL2; UNCLASSIFIED DRUG; FOXL2 PROTEIN, HUMAN; MUTANT PROTEIN; PEPTIDE;

ACETYLATION; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL NUCLEUS INCLUSION BODY; CELL STRUCTURE; CONTROLLED STUDY; NONHUMAN; PROMYELOCYTIC LEUKEMIA; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; SULFATION; SUMOYLATION; TANDEM MASS SPECTROMETRY; TRANSACTIVATION; AMINO ACID SEQUENCE; ANIMAL; CELL STRAIN COS1; CERCOPITHECUS; CHEMISTRY; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MASS SPECTROMETRY; METABOLISM; MOLECULAR GENETICS; PHOSPHORYLATION; PROTEIN TRANSPORT; TRANSCRIPTION INITIATION;

AMINO ACID SEQUENCE; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTRANUCLEAR INCLUSION BODIES; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; PEPTIDES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; PROTEIN TRANSPORT; SUMOYLATION; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 80053945453     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025463     Document Type: Article

References (65)

1. Cocquet J, Pailhoux E, Jaubert F, Servel N, Xia X, et al. (2002) Evolution and expression of FOXL2. J Med Genet 39: 916-921.
2. Ellsworth BS, Egashira N, Haller JL, Butts DL, Cocquet J, et al. (2006) FOXL2 in the pituitary: molecular, genetic, and developmental analysis. Mol Endocrinol 20: 2796-2805.
3. Crisponi L, Deiana M, Loi A, Chiappe F, Uda M, et al. (2001) The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 27: 159-166.
4. Zlotogora J, Sagi M, Cohen T, (1983) The blepharophimosis, ptosis, and epicanthus inversus syndrome: delineation of two types. Am J Hum Genet 35: 1020-1027.
5. Harris SE, Chand AL, Winship IM, Gersak K, Aittomäki K, et al. (2002) Identification of novel mutations in FOXL2 associated with premature ovarian failure. Mol Hum Reprod 8: 729-733.
6. Laissue P, Lakhal B, Benayoun BA, Dipietromaria A, Braham R, et al. (2009) Functional evidence implicating FOXL2 in non-syndromic premature ovarian failure and in the regulation of the transcription factor OSR2. J Med Genet 46: 455-457.
7. Uhlenhaut NH, Jakob S, Anlag K, Eisenberger T, Sekido R, et al. (2009) Somatic Sex Reprogramming of Adult Ovaries to Testes by FOXL2 Ablation. Cell 139: 1130-1142.
8. Ottolenghi C, Pelosi E, Tran J, Colombino M, Douglass E, et al. (2007) Loss of Wnt4 and Foxl2 leads to female-to-male sex reversal extending to germ cells. Hum Mol Genet 16: 2795-2804.
9. Schmidt D, Ovitt CE, Anlag K, Fehsenfeld S, Gredsted L, et al. (2004) The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance. Development 131: 933-942.
10. Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, et al. (2009) Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 360: 2719-2729.
11. Batista F, Vaiman D, Dausset J, Fellous M, Veitia RA, (2007) Potential targets of FOXL2, a transcription factor involved in craniofacial and follicular development, identified by transcriptomics. Proc Natl Acad Sci U S A 104: 3330-3335.
12. Benayoun BA, Batista F, Auer J, Dipietromaria A, L'Hôte D, et al. (2009) Positive and negative feedback regulates the transcription factor FOXL2 in response to cell stress: evidence for a regulatory imbalance induced by disease-causing mutations. Hum Mol Genet 18: 632-644.
13. Lee K, Pisarska MD, Ko J-J, Kang Y, Yoon S, et al. (2005) Transcriptional factor FOXL2 interacts with DP103 and induces apoptosis. Biochem Biophys Res Commun 336: 876-881.
14. Escudero JM, Haller JL, Clay CM, Escudero KW, (2010) Microarray analysis of Foxl2 mediated gene regulation in the mouse ovary derived KK1 granulosa cell line: Over-expression of Foxl2 leads to activation of the gonadotropin releasing hormone receptor gene promoter. J Ovarian Res 3: 4.
15. Pisarska MD, Kuo F-T, Bentsi-Barnes IK, Khan S, Barlow GM, (2010) LATS1 phosphorylates forkhead L2 and regulates its transcriptional activity. Am J Physiol Endocrinol Metab 299: E101-109.
16. Kuo F-T, Bentsi-Barnes IK, Barlow GM, Bae J, Pisarska MD, (2009) Sumoylation of forkhead L2 by Ubc9 is required for its activity as a transcriptional repressor of the Steroidogenic Acute Regulatory gene. Cell Signal 21: 1935-1944.
17. Marongiu M, Deiana M, Meloni A, Marcia L, Puddu A, et al. (2010) The forkhead transcription factor Foxl2 is sumoylated in both human and mouse: sumoylation affects its stability, localization, and activity. PLoS ONE 5: e9477.
18. Pisarska MD, Barlow G, Kuo F-T, (2011) Minireview: Roles of the Forkhead Transcription Factor FOXL2 in Granulosa Cell Biology and Pathology. Endocrinology 152: 1199-1208.
19. Benayoun BA, Veitia RA, (2009) A post-translational modification code for transcription factors: sorting through a sea of signals. Trends Cell Biol 19: 189-197.
20. Johnson ES, (2004) Protein modification by SUMO. Annu Rev Biochem 73: 355-382.
21. Kerscher O, Felberbaum R, Hochstrasser M, (2006) Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 22: 159-180.
22. Mukhopadhyay D, Dasso M, (2007) Modification in reverse: the SUMO proteases. Trends in Biochemical Sciences 32: 286-295.
23. Hay RT, (2005) SUMOA History of Modification. Molecular Cell 18: 1-12.
24. Garcia-Dominguez M, Reyes JC, (Juin) SUMO association with repressor complexes, emerging routes for transcriptional control. Biochimica et Biophysica Acta (BBA)- Gene Regulatory Mechanisms 1789: 451-459.
25. Stielow B, Sapetschnig A, Krüger I, Kunert N, Brehm A, et al. (2008) Identification of SUMO-dependent chromatin-associated transcriptional repression components by a genome-wide RNAi screen. Mol Cell 29: 742-754.
26. Hong Y, Rogers R, Matunis MJ, Mayhew CN, Goodson ML, et al. (2001) Regulation of heat shock transcription factor 1 by stress-induced SUMO-1 modification. J Biol Chem 276: 40263-40267.
27. Goodson ML, Hong Y, Rogers R, Matunis MJ, Park-Sarge OK, et al. (2001) Sumo-1 modification regulates the DNA binding activity of heat shock transcription factor 2, a promyelocytic leukemia nuclear body associated transcription factor. J Biol Chem 276: 18513-18518.
28. Terui Y, Saad N, Jia S, McKeon F, Yuan J, (2004) Dual role of sumoylation in the nuclear localization and transcriptional activation of NFAT1. J Biol Chem 279: 28257-28265.
29. Hattori T, Eberspaecher H, Lu J, Zhang R, Nishida T, et al. (2006) Interactions between PIAS proteins and SOX9 result in an increase in the cellular concentrations of SOX9. J Biol Chem 281: 14417-14428.
30. Garaude J, Farrás R, Bossis G, Charni S, Piechaczyk M, et al. (2008) SUMOylation regulates the transcriptional activity of JunB in T lymphocytes. J Immunol 180: 5983-5990.
31. Hwang EJ, Lee JM, Jeong J, Park JH, Yang Y, et al. (2009) SUMOylation of RORalpha potentiates transcriptional activation function. Biochem Biophys Res Commun 378: 513-517.
32. Batty E, Jensen K, Freemont P, (2009) PML nuclear bodies and their spatial relationships in the mammalian cell nucleus. Front Biosci 14: 1182-1196.
33. Lang M, Jegou T, Chung I, Richter K, Münch S, et al. (2010) Three-dimensional organization of promyelocytic leukemia nuclear bodies. J Cell Sci 123: 392-400.
34. Van Damme E, Laukens K, Dang TH, Van Ostade X, (2010) A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics. Int J Biol Sci 6: 51-67.
35. Negorev D, Maul GG, (2001) Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 20: 7234-7242.
36. Wójcik C, DeMartino GN, (2003) Intracellular localization of proteasomes. Int J Biochem Cell Biol 35: 579-589.
37. Ching RW, Dellaire G, Eskiw CH, Bazett-Jones DP, (2005) PML bodies: a meeting place for genomic loci? J Cell Sci 118: 847-854.
38. Bernardi R, Pandolfi PP, (2007) Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nature Reviews Molecular Cell Biology 8: 1006-1016.
39. Pisarska MD, Bae J, Klein C, Hsueh AJW, (2004) Forkhead l2 is expressed in the ovary and represses the promoter activity of the steroidogenic acute regulatory gene. Endocrinology 145: 3424-3433.
40. Nishi Y, Yanase T, Mu Y, Oba K, Ichino I, et al. (2001) Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor. Endocrinology 142: 437-445.
41. Mo Y-Y, Yu Y, Ee PLR, Beck WT, (2004) Overexpression of a dominant-negative mutant Ubc9 is associated with increased sensitivity to anticancer drugs. Cancer Res 64: 2793-2798.
42. Benayoun BA, Georges AB, L'hôte D, Andersson N, Dipietromaria A, et al. (2011) Transcription factor FOXL2 protects granulosa cells from stress and delays cell cycle: role of its regulation by the SIRT1 deacetylase. Hum Mol Genet 2011 May 1;20 (9): 1673-86.
43. Oberley LW, (2005) Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed Pharmacother 59: 143-148.
44. Lee CC, (2006) Tumor suppression by the mammalian Period genes. Cancer Causes Control 17: 525-530.
45. Beysen D, Moumné L, Veitia R, Peters H, Leroy BP, et al. (2008) Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation. Hum Mol Genet 17: 2030-2038.
46. Caburet S, Demarez A, Moumné L, Fellous M, De Baere E, et al. (2004) A recurrent polyalanine expansion in the transcription factor FOXL2 induces extensive nuclear and cytoplasmic protein aggregation. J Med Genet 41: 932-936.
47. Moumné L, Dipietromaria A, Batista F, Kocer A, Fellous M, et al. (2008) Differential aggregation and functional impairment induced by polyalanine expansions in FOXL2, a transcription factor involved in cranio-facial and ovarian development. Hum Mol Genet 17: 1010-1019.
48. Lamond AI, Spector DL, (2003) Nuclear speckles: a model for nuclear organelles. Nat Rev Mol Cell Biol 4: 605-612.
49. Morris GE, (2008) The Cajal body. Biochim Biophys Acta 1783: 2108-2115.
50. Sutherland H, Bickmore WA, (2009) Transcription factories: gene expression in unions? Nat Rev Genet 10: 457-466.
51. Condemine W, Takahashi Y, Zhu J, Puvion-Dutilleul F, Guegan S, et al. (2006) Characterization of Endogenous Human Promyelocytic Leukemia Isoforms. Cancer Res 66: 6192-6198.
52. Strott CA, (2002) Sulfonation and Molecular Action. Endocrine Reviews 23: 703-732.
53. Medzihradszky KF, Darula Z, Perlson E, Fainzilber M, Chalkley RJ, et al. (2004) O-Sulfonation of Serine and Threonine. Molecular & Cellular Proteomics 3: 429-440.
54. Xue Y, Ren J, Gao X, Jin C, Wen L, et al. (2008) GPS 2.0, a tool to predict kinase-specific phosphorylation sites in hierarchy. Mol Cell Proteomics 7: 1598-1608.
55. Kannan N, Neuwald AF, (2004) Evolutionary constraints associated with functional specificity of the CMGC protein kinases MAPK, CDK, GSK, SRPK, DYRK, and CK2alpha. Protein Sci 13: 2059-2077.
56. Tao W, Zhang S, Turenchalk GS, Stewart RA, St John MA, et al. (1999) Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity. Nat Genet 21: 177-181.
57. Kumar A, Babu M, Raghunath A, Venkatesh CP, (2004) Genetic analysis of a five generation Indian family with BPES: a novel missense mutation (p. Y215C). Mol Vis 10: 445-449.
58. Bundgaard JR, Sen JW, Johnsen AH, Rehfeld JF, (2008) Analysis of Tyrosine-O-Sulfation. In: Kannicht C, editors. Post-translational Modifications of Proteins Totowa, NJ Humana Press pp. 47-66.
59. Dave KA, Whelan F, Bindloss C, Furness SGB, Chapman-Smith A, et al. (2009) Sulfonation and Phosphorylation of Regions of the Dioxin Receptor Susceptible to Methionine Modifications. Mol Cell Proteomics 8: 706-719.
60. Thompson PR, Kurooka H, Nakatani Y, Cole PA, (2001) Transcriptional coactivator protein p300. Kinetic characterization of its histone acetyltransferase activity. J Biol Chem 276: 33721-33729.
61. Kim HP, Roe JH, Chock PB, Yim MB, (1999) Transcriptional activation of the human manganese superoxide dismutase gene mediated by tetradecanoylphorbol acetate. J Biol Chem 274: 37455-37460.
62. Yoo S-H, Ko CH, Lowrey PL, Buhr ED, Song E-joo, et al. (2005) A noncanonical E-box enhancer drives mouse Period2 circadian oscillations in vivo. Proc Natl Acad Sci U S A 102: 2608-2613.
63. Itahana Y, Yeh ETH, Zhang Y, (2006) Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol Cell Biol 26: 4675-4689.
64. Janer A, Martin E, Muriel M-P, Latouche M, Fujigasaki H, et al. (2006) PML clastosomes prevent nuclear accumulation of mutant ataxin-7 and other polyglutamine proteins. J Cell Biol 174: 65-76.
65. Sambrook J, Russell DW, (2001) Molecular Cloning: a laboratory manual, 3rd edition Cold Spring Harobor Cold Spring Harbor Laboratory Press.